title: The Impact of Inherited Thrombophilia Types and Low Molecular Weight Heparin Treatment on Pregnancy Complications in Women with Previous Adverse Outcome.
abstract: OBJECTIVE
  To assess the distribution of births and spontaneous abortions, first-trimester abortion (FTA) and mid-trimester abortion (MTA), in untreated (n=128) and low molecular weight heparin (LMWH) treated pregnancies (n=50) of the same women with inherited thrombophilias and adverse pregnancy outcome (APO) in previous pregnancies. We particularly investigated the impact of LMWH on reducing the pregnancy complications in two thrombophilia types, "Conventional" and "Novel".
  
  
  METHODS
  50 women with inherited thrombophilia (26 Conventional and 24 Novel) and APO in previous pregnancies were included in the study. Conventional group included factor V Leiden (FVL), prothrombin G20210A (PT) mutations and antithrombin (AT), protein S (PS), and protein C (PC) deficiency, while the Novel group included methylentetrahydrofolate-reductase (MTHFR), plasminogen activator inhibitor-1 (PAI-1), and angiotensin converting enzyme (ACE) polymorphism. APO was defined as one of the following: preterm birth (PTB), fetal growth restriction (FGR), preeclampsia (PE), intrauterine fetal death (IUFD), placental abruption (PA) and deep venous thrombosis (DVT).
  
  
  RESULTS
  There was no difference in distribution of births and spontaneous abortions between Conventional and Novel thrombophilia in untreated pregnancies (χ²=2.7; p=0.100) and LMWH treated pregnancies (χ²=0.442; p=0.506). In untreaed pregnancies thrombophilia type did not have any impact on the frequency of FTA and MTA (χ²=0.14; p=0.711). In birth-ended pregnancies LMWH treatement reduced the incidence of IUFD (p=0.011) in Conventional and FGR, IUFD, and PTB in Novel thrombophilia group.
  
  
  CONCLUSIONS
  The equal impact of two thrombophilia types on the pregnancy outcomes and a more favorable effect of LMWH therapy on pregnancy complications in Novel thrombophilia group point the need for Novel thrombophilias screening and the future studies on this issue should be recommended.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Split, Croatia.|Polyclinic Cito, Split, Croatia.
authors.forename: Nada
authors.initials: N
authors.lastname: Aracic
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Split, Croatia.
authors.forename: Damir
authors.initials: D
authors.lastname: Roje
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Split, Croatia.
authors.forename: Ivana Alujevic
authors.initials: IA
authors.lastname: Jakus
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Split, Croatia.
authors.forename: Marinela
authors.initials: M
authors.lastname: Bakotin
authors.affiliation: Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland. vedran.stefanovic@yahoo.com.
authors.forename: Vedran
authors.initials: V
authors.lastname: Stefanovic
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D011110:Polymorphism, Genetic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000235:genetics; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000188:drug therapy* / Q000235:genetics; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight
keywords: LMWH; Thrombophilia; pregnancy outcome